Hydralazine injection labels and packages: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Hydralazine}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIU..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
PACKAGE LABEL - PRINCIPAL DISPLAY - Hydralazine Hydrochloride 1 mL Single Dose Vial Label | |||
NDC 63323-614-55 | |||
NP601401 | |||
hydrALAZINE HYDROCHLORIDE INJECTION, USP | |||
20 mg/mL | |||
FOR IM OR IV USE | |||
1 mL Rx only | |||
Single Dose Vial | |||
WARNING: DISCARD UNUSED PORTION. | |||
{| | |||
| [[image:hydra9.jpg|400px|thumb]] | |||
|} | |||
PACKAGE LABEL - PRINCIPAL DISPLAY - Hydralazine Hydrochloride 1 mL Single Dose Vial Tray Label | |||
NDC 63323-614-55 | |||
NP601401 | |||
hydrALAZINE HYDROCHLORIDE INJECTION, USP | |||
FOR INTRAMUSCULAR OR INTRAVENOUS USE | |||
20 mg/mL | |||
1 mL Single Dose Vial | |||
N+ and NOVAPLUS are registered trademarks of Novation, LLC | |||
Rx only | |||
{| | |||
| [[image:hydra10.png|400px|thummb]] | |||
|} | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3797028-c625-4f70-ae69-8a5f6f23f1b8 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3797028-c625-4f70-ae69-8a5f6f23f1b8 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | ||
Revision as of 06:31, 11 March 2014
| Hydralazine |
|---|
| HYDRALAZINE tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| HYDRALAZINE injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Hydralazine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
PACKAGE LABEL - PRINCIPAL DISPLAY - Hydralazine Hydrochloride 1 mL Single Dose Vial Label
NDC 63323-614-55
NP601401
hydrALAZINE HYDROCHLORIDE INJECTION, USP 20 mg/mL
FOR IM OR IV USE
1 mL Rx only
Single Dose Vial WARNING: DISCARD UNUSED PORTION.
 |
PACKAGE LABEL - PRINCIPAL DISPLAY - Hydralazine Hydrochloride 1 mL Single Dose Vial Tray Label NDC 63323-614-55
NP601401
hydrALAZINE HYDROCHLORIDE INJECTION, USP
FOR INTRAMUSCULAR OR INTRAVENOUS USE
20 mg/mL
1 mL Single Dose Vial
N+ and NOVAPLUS are registered trademarks of Novation, LLC
Rx only
| thummb |
References
- ↑ "HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC]". Retrieved 10 March 2014.